Equities Analysts Set Expectations for VERA Q2 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA) – Equities researchers at Lifesci Capital issued their Q2 2025 earnings estimates for Vera Therapeutics in a report released on Monday, June 2nd. Lifesci Capital analyst R. Katkhuda expects that the company will post earnings per share of ($0.82) for the quarter. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. Lifesci Capital also issued estimates for Vera Therapeutics’ Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.85) EPS and FY2025 earnings at ($3.32) EPS.

Other research analysts have also issued research reports about the company. HC Wainwright lifted their target price on Vera Therapeutics from $75.00 to $85.00 and gave the stock a “buy” rating in a research report on Monday. JPMorgan Chase & Co. decreased their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating for the company in a report on Tuesday, March 4th. Scotiabank boosted their target price on shares of Vera Therapeutics from $55.00 to $65.00 and gave the company a “sector outperform” rating in a research note on Monday. Guggenheim raised their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Finally, Cantor Fitzgerald lowered their price objective on shares of Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating for the company in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $65.00.

Vera Therapeutics Stock Down 2.6%

NASDAQ:VERA opened at $30.91 on Tuesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of -11.84 and a beta of 1.28. Vera Therapeutics has a one year low of $18.53 and a one year high of $51.61. The stock has a 50-day simple moving average of $22.15 and a 200 day simple moving average of $31.86.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the prior year, the company earned ($0.56) EPS.

Institutional Investors Weigh In On Vera Therapeutics

Large investors have recently made changes to their positions in the company. Barclays PLC grew its holdings in Vera Therapeutics by 94.1% in the 3rd quarter. Barclays PLC now owns 85,395 shares of the company’s stock worth $3,774,000 after buying an additional 41,394 shares in the last quarter. KBC Group NV boosted its position in Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after acquiring an additional 1,387 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Vera Therapeutics by 27.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,427 shares of the company’s stock worth $568,000 after purchasing an additional 2,882 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Vera Therapeutics by 82.0% during the fourth quarter. Jennison Associates LLC now owns 813,861 shares of the company’s stock valued at $34,418,000 after purchasing an additional 366,763 shares during the period. Finally, Legato Capital Management LLC increased its holdings in shares of Vera Therapeutics by 56.0% during the fourth quarter. Legato Capital Management LLC now owns 13,454 shares of the company’s stock valued at $569,000 after purchasing an additional 4,831 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.